The Patent Finder

Terms ending in 2039

Anavex Life Sciences Corp.

Every in-force patent on Anavex Life Sciences Corp.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 12,280,034SIGMA-1 Receptor Agonist Systolic Blood Pressure Therapy
In force
 · High confidence
Anavex Life Sciences Corp.In forceHigh confidence
US 11,622,955SIGMA-1 Receptor Agonist Systolic Blood Pressure Therapy
In force
 · High confidence
Anavex Life Sciences Corp.In forceHigh confidence
US 12,180,174A2-73 Crystalline Polymorph Compositions of Matter and Methods of Use Thereof
In force
 · High confidence
Anavex Life Sciences Corp.In forceHigh confidence
US 12,138,240Treatment of Cardiac Dysfunction
In force
 · Medium confidence
Anavex Life Sciences Corp.In forceMedium confidence
US 11,498,908A2-73 Crystalline Polymorph Compositions of Matter and Methods of Use Thereof
In force
 · High confidence
Anavex Life Sciences Corp.In forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited